Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postmenopausal HR-positive HER2-negative breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.09.19
Views: 523
Rating:

Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, California

Prof Dennis Slamon presents data from the MONALEESA-3 trial during a press conference at the 2019 ESMO congress.

This was a trial looking at treatment with the CDK4/6 inhibitor ribociclib plus fulvestrant in postmenopausal patients with HR HER2- advanced breast cancer.

Watch Prof Slamon's interview with ecancer here.

Read more on this study here.

 

Related videos

follow us

Biosimilar Medicines Core Principles and Communication


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation